Loading...
NPI 1881105013 · Blue Ash, OH · Acute Care Nurse Practitioner
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jody Huss is a acute care nurse practitioner provider located in Blue Ash, Ohio. This profile covers 17 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jody Huss |
| Address | 4260 Glendale Milford Rd Ste 1007 |
| City | Blue Ash |
| State | OH |
| ZIP | 45242 |
| Taxonomy | Acute Care Nurse Practitioner |
| NPI Enumerated | October 16, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.9M |
| Medicaid | $2.2K |
This provider’s billing profile is dominated by Medicare specialty drug administration rather than routine evaluation-and-management visits: total Medicare revenue is $1.9M and the top revenue-driving codes are injectable biologics such as J3245, J0897, and J2357, with the precomputed top-3 Medicare codes accounting for 42.9% of Medicare revenue. The mix of drugs billed (tildrakizumab, denosumab, omalizumab, abatacept, tezepelumab, immune globulin, inclisiran, etc.) points to a practice model focused on in-clinic administration of specialty biologics across immunology, dermatology, rheumatology and bone-health indications rather than a high volume of traditional office-only services.
Revenue concentration on Medicare is substantial: the three highest-revenue Medicare codes together make up 42.9% of this provider’s Medicare revenue, with J3245 reported at 3.3K claims, $110 avg paid/claim, $363K revenue (19.5% of Medicare revenue) and J0897 and J2357 contributing $226.8K (12.2%) and $209.7K (11.3%) respectively. That concentration indicates a relatively narrow set of drug therapies drives a large share of billings, which has implications for payer negotiation and utilization review focused on these agents.
Payer mix is heavily Medicare-weighted: total Medicare revenue is $1.9M compared with total Medicaid revenue of $2.2K, so this provider is effectively single-payer-dominant with Medicare representing the overwhelming share of recorded public-payer activity. Medicaid activity exists but is minimal in scale, suggesting limited participation in state Medicaid programs or a patient panel composed primarily of Medicare beneficiaries.
Competitive standing varies by drug: for denosumab (J0897) the provider ranks #760 of 10057 nationally (92th percentile), indicating well-above-average national volume for that drug, whereas for tildrakizumab (J3245) the provider ranks #135 of 225 (38th percentile), a modest position among peers. Other Medicare drug ranks such as J2357 at #179 of 581 (69th percentile) and J1569 at #159 of 542 (71st percentile) show several mid-to-high percentile positions, consistent with a focused but not dominant national footprint across multiple specialty biologics.
There is a notable statistical outlier on the Medicare side for injection administration: code 96372 appears as an extreme outlier with 809 claims, $8 avg paid/claim, $6.5K revenue and a national rank of #655 of 58224 (99th percentile), meaning the provider bills intramuscular/subcutaneous injections at far higher volume than typical peers under Medicare. By contrast, the same code under Medicaid represents the provider’s entire Medicaid revenue (122 claims, $18 avg paid/claim, $2.2K revenue) and ranks #559 of 843 in-state (34th percentile), so the injection volume is exceptional only in the Medicare dataset, not in-state Medicaid benchmarks.
Service-line implications from the paid-claim mix support an infusion/administration business model: frequent use of codes tied to clinic-administered biologics (for example J0129 abatacept at 6.2K claims and $209.1K revenue, J2356 tezepelumab-ekko at 14.7K claims and $205.8K revenue) suggests the provider operates where in-office drug delivery is a core service rather than dispensing self-administered prescriptions. Payers reviewing utilization should prioritize these administration and high-cost biologic codes when assessing medical necessity and site-of-care appropriateness.
Medicaid billing is effectively concentrated entirely in one administration code: the precomputed top-3 Medicaid codes account for 100.0% of Medicaid revenue, and that is entirely represented by 96372 (122 claims, $18 avg paid/claim, $2.2K revenue). This pattern indicates minimal Medicaid exposure and suggests Medicaid policy or contracting will have limited financial impact relative to Medicare for this provider.
Tenure and enrollment are straightforward: the provider’s NPI was enumerated on 2017-10-16 (~9 years ago), so this billing history reflects several years of Medicare activity and establishes a multi-year presence in the Medicare provider population, which supports trend-based review of specialty-drug utilization over time.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | 3,300 | $110 | $363K |
| J0897 | Injection, denosumab, 1 mg | 12,600 | $20 | $226.8K |
| J2357 | Injection, omalizumab, 5 mg | 6,990 | $30 | $209.7K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 6,150 | $30 | $209.1K |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 14,700 | $10 | $205.8K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 5,490 | $40 | $197.6K |
| J1306 | Injection, inclisiran, 1 mg | 17,610 | $10 | $158.5K |
| J0485 | Injection, belatacept, 1 mg | 36,300 | $1 | $108.9K |
| J0517 | Injection, benralizumab, 1 mg | 600 | $130 | $80.4K |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 7,770 | $10 | $62.2K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J3245 | 5 | 10 | 3,300 | $110 | $431.5K |
| J0129 | 23 | 40 | 7,360 | $30 | $290K |
| J3111 | 16 | 20 | 15,540 | $10 | $246.6K |
| J2357 | 5 | 10 | 8,430 | $30 | $230.4K |
| J1569 | 6 | 20 | 4,900 | $40 | $203.8K |
| J0517 | 2 | 10 | 1,340 | $130 | $176.8K |
| J2356 | 2 | 10 | 10,190 | $10 | $153.2K |
| J0485 | 1 | 10 | 36,300 | $1 | $107.6K |
| J1306 | 2 | 10 | 7,380 | $10 | $83.4K |
| J0897 | 14 | 230 | 2,880 | $20 | $79.5K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 120 | $20 | $2.2K |
How this provider's Medicaid billing volume and revenue compare to other Ohio providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Ohio median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 559 | 840 | 350 | $10 | $13.8K |
Other providers in the same ZIP code as Jody Huss, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.